Standout Papers

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Me... 2012 2026 2016 2021 356
  1. Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes (2012)
    Julio Rosenstock, Naresh Aggarwal et al. Diabetes Care

Immediate Impact

4 from Science/Nature 107 standout
Sub-graph 1 of 18

Citing Papers

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
2024 Standout
Blinded, randomized trial of sonographer versus AI cardiac function assessment
2023 StandoutNature
1 intermediate paper

Works of George Capuano being referenced

Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes
2015
Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome
2001

Author Peers

Author Last Decade Papers Cites
George Capuano 1072 582 505 25 1.6k
Sunder Mudaliar 1138 573 501 21 1.6k
Alan Rees 401 658 255 36 1.7k
Alexandra Ward 299 182 391 51 1.9k
Michael Gaffney 553 428 95 24 1.8k
David S Celermajer 406 232 146 23 1.7k
Nunziata Morabito 410 111 388 41 1.9k
P. D. Home 975 418 386 46 1.5k
Richard F. Spark 1287 431 283 42 2.0k
Jingping Mo 273 198 123 29 1.7k
Ernest V. Gervino 183 307 327 44 2.1k

All Works

Loading papers...

Rankless by CCL
2026